Grace Therapeutics (NASDAQ:GRCE – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 259.28% from the stock’s current price.
Grace Therapeutics Stock Performance
Shares of GRCE opened at $3.34 on Tuesday. Grace Therapeutics has a fifty-two week low of $2.13 and a fifty-two week high of $4.97. The company has a fifty day moving average of $3.66. The firm has a market cap of $33.87 million, a price-to-earnings ratio of -2.88 and a beta of 1.36.
Grace Therapeutics (NASDAQ:GRCE – Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Equities research analysts anticipate that Grace Therapeutics will post -0.98 EPS for the current year.
Grace Therapeutics Company Profile
Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.
Featured Articles
- Five stocks we like better than Grace Therapeutics
- Transportation Stocks Investing
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- How to Choose Top Rated Stocks
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
